Randomized, Open, Clinical Study to Evaluate the Safety and Immunogenecity of an Inactivated Split-virion Influenza A(H1N1) Vaccine GC1116 With Adjuvant in Healthy Adults.
Phase of Trial: Phase III
Latest Information Update: 02 Jan 2018
At a glance
- Drugs Influenza A virus vaccine-H1N1 (Primary) ; Adjuvants
- Indications Influenza A virus H1N1 subtype
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors GC Pharma; Green Cross
- 02 Jan 2018 According to a GC Pharma media release, Green Cross Corporation rebrands itself to GC Pharma.
- 24 Sep 2010 New trial record